These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 30232224)

  • 1. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
    Beltran H; Oromendia C; Danila DC; Montgomery B; Hoimes C; Szmulewitz RZ; Vaishampayan U; Armstrong AJ; Stein M; Pinski J; Mosquera JM; Sailer V; Bareja R; Romanel A; Gumpeni N; Sboner A; Dardenne E; Puca L; Prandi D; Rubin MA; Scher HI; Rickman DS; Demichelis F; Nanus DM; Ballman KV; Tagawa ST
    Clin Cancer Res; 2019 Jan; 25(1):43-51. PubMed ID: 30232224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
    Lin J; Patel SA; Sama AR; Hoffman-Censits JH; Kennedy B; Kilpatrick D; Ye Z; Yang H; Mu Z; Leiby B; Lewis N; Cristofanilli M; Kelly WK
    Oncologist; 2016 Nov; 21(11):1296-1297e. PubMed ID: 28178640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
    Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
    Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
    Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J
    EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
    Yin Y; Xu L; Chang Y; Zeng T; Chen X; Wang A; Groth J; Foo WC; Liang C; Hu H; Huang J
    Mol Cancer; 2019 Jan; 18(1):11. PubMed ID: 30657058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.
    Melichar B; Adenis A; Lockhart AC; Bennouna J; Dees EC; Kayaleh O; Obermannova R; DeMichele A; Zatloukal P; Zhang B; Ullmann CD; Schusterbauer C
    Lancet Oncol; 2015 Apr; 16(4):395-405. PubMed ID: 25728526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
    Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
    Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
    Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
    Dickson MA; Mahoney MR; Tap WD; D'Angelo SP; Keohan ML; Van Tine BA; Agulnik M; Horvath LE; Nair JS; Schwartz GK
    Ann Oncol; 2016 Oct; 27(10):1855-60. PubMed ID: 27502708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
    Zhang W; Liu B; Wu W; Li L; Broom BM; Basourakos SP; Korentzelos D; Luan Y; Wang J; Yang G; Park S; Azad AK; Cao X; Kim J; Corn PG; Logothetis CJ; Aparicio AM; Chinnaiyan AM; Navone N; Troncoso P; Thompson TC
    Clin Cancer Res; 2018 Feb; 24(3):696-707. PubMed ID: 29138344
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
    DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
    J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
    Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
    J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
    Davis SL; Ionkina AA; Bagby SM; Orth JD; Gittleman B; Marcus JM; Lam ET; Corr BR; O'Bryant CL; Glode AE; Tan AC; Kim J; Tentler JJ; Capasso A; Lopez KL; Gustafson DL; Messersmith WA; Leong S; Eckhardt SG; Pitts TM; Diamond JR
    Clin Cancer Res; 2020 Sep; 26(17):4633-4642. PubMed ID: 32414750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
    Brady NJ; Bagadion AM; Singh R; Conteduca V; Van Emmenis L; Arceci E; Pakula H; Carelli R; Khani F; Bakht M; Sigouros M; Bareja R; Sboner A; Elemento O; Tagawa S; Nanus DM; Loda M; Beltran H; Robinson B; Rickman DS
    Nat Commun; 2021 Jun; 12(1):3372. PubMed ID: 34099734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
    Graff JN; Higano CS; Hahn NM; Taylor MH; Zhang B; Zhou X; Venkatakrishnan K; Leonard EJ; Sarantopoulos J
    Cancer; 2016 Aug; 122(16):2524-33. PubMed ID: 27192055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
    Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
    Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.
    Xu P; Yang JC; Chen B; Ning S; Zhang X; Wang L; Nip C; Shen Y; Johnson OT; Grigorean G; Phinney B; Liu L; Wei Q; Corey E; Tepper CG; Chen HW; Evans CP; Dall'Era MA; Gao AC; Gestwicki JE; Liu C
    Nat Commun; 2024 Aug; 15(1):6626. PubMed ID: 39103353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.